Browsing by Subject "BNT162b2"
Now showing items 1-4 of 4
-
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.
( Nature Researc , 2021 , Article)With the global expansion of the highly transmissible SARS-CoV-2 Delta (B.1.617.2) variant, we conducted a matched test-negative case-control study to assess the real-world effectiveness of COVID-19 messenger RNA vaccines ... -
Clinical outcomes of Pfizer-BioNTech COVID-19 vaccine in children and adolescents: A systematic review
( John Wiley and Sons Inc , 2022 , Article Review)Background & Aims: The BioNTech-Pfizer vaccine is the only vaccine offered to children among all available vaccines. However, limited evidence is available about the clinical outcomes of COVID-19 vaccines, especially among ... -
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants.
( Massachusetts Medical Society , 2021 , Other)The messenger RNA vaccine BNT162b2 (Pfizer–BioNTech) has 95% efficacy against coronavirus disease 2019 (Covid-19). Qatar launched a mass immunization campaign with this vaccine on December 21, 2020. As of March 31, 2021, ... -
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar.
( Massachusetts Medical Society , 2021 , Article)Waning of vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (Covid-19) is a concern. The persistence of BNT162b2 (Pfizer-BioNTech) vaccine ...